Health & Biotech

Dr Boreham’s Crucible: Does Osprey Medical’s GPO deal mean the cheque is in the US mail?

April 15, 2019April 14, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: You can get BV any old how, but Starpharma’s here to help

April 8, 2019April 7, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Immutep’s booked itself in for several shots in 2019

April 1, 2019March 31, 2019 | Tim Boreham

Dr Boreham’s Crucible: Rhinomed has the goods to deliver anything… nasally

March 25, 2019March 24, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Trial results could be the US leg-up Volpara’s looking for

March 11, 2019March 18, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Is Cochlear’s journey a blueprint for Nuheara’s success?

March 4, 2019March 18, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: 13 years on, Cellmid’s finally looking groomed for success

February 25, 2019March 18, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: What the biotech minnows can learn from the $84 billion market cap CSL

February 18, 2019March 18, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: The fact Adalta’s still afloat makes it a tasty prospect

February 11, 2019March 18, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: How $18bn snore buster ResMed stacks up against ASX sleep minnows

February 4, 2019March 18, 2019 | Tim Boreham

Health & Biotech

Tim Boreham: Sperm sorter Memphasys is finding its feet as a grower, not a shower

January 10, 2019March 19, 2019 | Tim Boreham

Health & Biotech

Allegra hops closer to implanting kangaroo tendons in people

January 9, 2019March 19, 2019 | Tim Boreham